Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10739591 | 0.85 | CYP2C19 (0.41) | SLC6A2SLC6A4SLC6A3ANPEP | |
| SCHEMBL10738693 | 0.83 | NR3C2 (0.33) | IDO1 | |
| SCHEMBL14416002 | 0.82 | SLC15A1 (0.40) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL9121119 | 0.82 | FAAH (0.45) | TRPA1 | |
| SCHEMBL10744668 | 0.81 | TAAR1 (0.37) | IDO1CYP1A2ALPITAAR1 | |
| SCHEMBL9570053 | 0.81 | CYP1A2 (0.36) | CYP1A2CPA1EPHX1ALPIPKM | |
| SCHEMBL1484177 | 0.81 | SLC6A2 (0.49) | CYP1A2EPHX1SLC6A2TAAR1SLC6A4 | |
| SCHEMBL10743814 | 0.79 | SLC6A2 (0.34) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL8762076 | 0.79 | CPA1 (0.51) | CYP1A2CPA1EPHX1ALPIPKM | |
| SCHEMBL10744482 | 0.79 | IDO1 (0.36) | IDO1SLC6A2TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | claimed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | claimed |
| CN-101578271-A | 4-imidazolines as TAAR's ligands | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | CN | claimed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | claimed |
| CN-101578271-B | 4-imidazolines as taar's ligands | HOFFMANN LA ROCHE | 2013-06-19 | — | — | CN | disclosed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| CN-101578271-A | 4-imidazolines as TAAR's ligands | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | CN | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
| US-4684659-A | Antimypertensive substituted imidazoles | FARMOS-YHTYMA OY (FI) | 1987-08-04 | — | — | US | disclosed |
| US-4568686-A | Substituted imidazoles and their use | FARMOS YHTYMA OY (FI) | 1986-02-04 | — | — | US | disclosed |
| EP-0034473-B1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Farmos-Yhtyma Oy (FI) | 1983-09-21 | — | — | EP | disclosed |
| EP-0034473-A2 | Substituted imidazoles, their preparation and pharmaceutical compositions containing the same | Farmos-Yhtyma Oy (FI) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | IDO1 114/4885CYP1A2 435/4885TRPA1 164/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | IDO1 114/4885CYP1A2 435/4885TRPA1 164/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | IDO1 114/4885CYP1A2 435/4885TRPA1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.